These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 19364960)

  • 1. Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer.
    Morris MJ; Pandit-Taskar N; Carrasquillo J; Divgi CR; Slovin S; Kelly WK; Rathkopf D; Gignac GA; Solit D; Schwartz L; Stephenson RD; Hong C; Delacruz A; Curley T; Heller G; Jia X; O'Donoghue J; Larson S; Scher HI
    J Clin Oncol; 2009 May; 27(15):2436-42. PubMed ID: 19364960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repetitively dosed docetaxel and ¹⁵³samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer.
    Autio KA; Pandit-Taskar N; Carrasquillo JA; Stephenson RD; Slovin SF; Rathkopf DE; Hong C; Heller G; Scher HI; Larson SM; Morris MJ
    Cancer; 2013 Sep; 119(17):3186-94. PubMed ID: 23765638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial with a combination of docetaxel and ¹⁵³Sm-lexidronam in patients with castration-resistant metastatic prostate cancer.
    Lin J; Sinibaldi VJ; Carducci MA; Denmeade S; Song D; Deweese T; Eisenberger MA
    Urol Oncol; 2011; 29(6):670-5. PubMed ID: 19962920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer.
    Tu SM; Mathew P; Wong FC; Jones D; Johnson MM; Logothetis CJ
    J Clin Oncol; 2009 Jul; 27(20):3319-24. PubMed ID: 19414670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer.
    Fizazi K; Beuzeboc P; Lumbroso J; Haddad V; Massard C; Gross-Goupil M; Di Palma M; Escudier B; Theodore C; Loriot Y; Tournay E; Bouzy J; Laplanche A
    J Clin Oncol; 2009 May; 27(15):2429-35. PubMed ID: 19364971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety analysis of repeated high doses of samarium-153 lexidronam in men with hormone-naive prostate cancer metastatic to bone.
    Higano CS; Quick DP; Bushnell D; Sartor O
    Clin Genitourin Cancer; 2008 Mar; 6(1):40-5. PubMed ID: 18501082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and antitumor efficacy of (153)Sm-EDTMP and docetaxel administered sequentially to patients with metastatic castration-resistant prostate cancer.
    Borsò E; Boni G; Pastina I; Lorenzoni A; Cianci C; Federici F; Mazzarri S; Orlandini C; Francesca F; Selli C; Ricci S; Rubello D; Mariani G
    Nucl Med Commun; 2014 Jan; 35(1):88-94. PubMed ID: 24157942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Samarium-153-EDTMP (Quadramet®) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial.
    Heery CR; Madan RA; Stein MN; Stadler WM; Di Paola RS; Rauckhorst M; Steinberg SM; Marté JL; Chen CC; Grenga I; Donahue RN; Jochems C; Dahut WL; Schlom J; Gulley JL
    Oncotarget; 2016 Oct; 7(42):69014-69023. PubMed ID: 27486817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biodistribution of samarium-153-EDTMP in rats treated with docetaxel.
    Villarim Neto A; Açucena MK; Pereira KR; Rêgo AC; Azevedo IM; Bernardo-Filho M; Medeiros AC
    Acta Cir Bras; 2009; 24(1):62-6. PubMed ID: 19169545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase I trial of samarium-153-lexidronam complex for treatment of clinically nonmetastatic high-risk prostate cancer: first report of a completed study.
    Valicenti RK; Trabulsi E; Intenzo C; Lavarino J; Xu Y; Chervoneva I
    Int J Radiat Oncol Biol Phys; 2011 Mar; 79(3):732-7. PubMed ID: 20399029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer.
    Mathew P; Thall PF; Jones D; Perez C; Bucana C; Troncoso P; Kim SJ; Fidler IJ; Logothetis C
    J Clin Oncol; 2004 Aug; 22(16):3323-9. PubMed ID: 15310776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study.
    Araujo JC; Mathew P; Armstrong AJ; Braud EL; Posadas E; Lonberg M; Gallick GE; Trudel GC; Paliwal P; Agrawal S; Logothetis CJ
    Cancer; 2012 Jan; 118(1):63-71. PubMed ID: 21976132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 1/1b study of satraplatin (JM-216) in combination with docetaxel in patients with advanced solid tumors and metastatic castrate-resistant prostate cancer.
    Cetnar J; Wilding G; McNeel D; LoConte NK; McFarland TA; Eickhoff J; Liu G
    Urol Oncol; 2013 May; 31(4):436-41. PubMed ID: 21481618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
    Efstathiou E; Bozas G; Kostakopoulos A; Kastritis E; Deliveliotis C; Antoniou N; Skarlos D; Papadimitriou C; Dimopoulos MA; Bamias A
    Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is ¹⁵³Samarium-ethylene-diamine-tetramethyl-phosphonate (EDTMP) bone uptake influenced by bisphosphonates in patients with castration-resistant prostate cancer?
    Waldert M; Klatte T; Remzi M; Sinzinger H; Kratzik C
    World J Urol; 2012 Apr; 30(2):233-7. PubMed ID: 21559805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective evaluation of samarium-153-EDTMP radionuclide treatment for bone metastases in patients with hormone-refractory prostate cancer.
    Dolezal J; Vizda J; Odrazka K
    Urol Int; 2007; 78(1):50-7. PubMed ID: 17192733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer.
    Rathkopf D; Wong BY; Ross RW; Anand A; Tanaka E; Woo MM; Hu J; Dzik-Jurasz A; Yang W; Scher HI
    Cancer Chemother Pharmacol; 2010 May; 66(1):181-9. PubMed ID: 20217089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer.
    Armstrong AJ; Creel P; Turnbull J; Moore C; Jaffe TA; Haley S; Petros W; Yenser S; Gockerman JP; Sleep D; Hurwitz H; George DJ
    Clin Cancer Res; 2008 Oct; 14(19):6270-6. PubMed ID: 18829508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial.
    Zurita AJ; George DJ; Shore ND; Liu G; Wilding G; Hutson TE; Kozloff M; Mathew P; Harmon CS; Wang SL; Chen I; Chow Maneval E; Logothetis CJ
    Ann Oncol; 2012 Mar; 23(3):688-694. PubMed ID: 21821830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases.
    Anderson PM; Wiseman GA; Dispenzieri A; Arndt CA; Hartmann LC; Smithson WA; Mullan BP; Bruland OS
    J Clin Oncol; 2002 Jan; 20(1):189-96. PubMed ID: 11773169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.